Endothelial Activation by aPL: A Potential Pathogenetic Mechanism for the Clinical Manifestations of the Syndrome
It is now generally accepted that antiphospholipid antibodies (aPL) rather than to be directed against PL themselves do recogize PL-binding proteins; beta sub(2)-Glycoprotein I ( beta sub(2)-GPI) has been shown to be the most important. beta sub(2)-Glycoprotein I is a highly cationic glycoprotein no...
Gespeichert in:
| Veröffentlicht in: | Journal of Autoimmunity 2000-09, Vol.15 (2), p.237-240 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 240 |
|---|---|
| container_issue | 2 |
| container_start_page | 237 |
| container_title | Journal of Autoimmunity |
| container_volume | 15 |
| creator | Meroni, P.L Raschi, E Camera, M Testoni, C Nicoletti, F Tincani, A Khamashta, M.A Balestrieri, G Tremoli, E Hess, D.C |
| description | It is now generally accepted that antiphospholipid antibodies (aPL) rather than to be directed against PL themselves do recogize PL-binding proteins; beta sub(2)-Glycoprotein I ( beta sub(2)-GPI) has been shown to be the most important. beta sub(2)-Glycoprotein I is a highly cationic glycoprotein normally present in the serum and able to bind anionic structures including negatively charged PL. It displays several activities potentially related to the pathphysiology of the antiphospholipid symdrome (APS) by: (a) acting as a natural circulating anticoagulant, (b) potentiating platelet activation, and (c) interfering with the protein C/S system. More recently, beta sub(2)-GPI was found to adhere to human endothelial and trophoblast cell membranes and to offer suitable epitopes for circulating anti- beta sub(2)-GPI antibodies. The antibody binding to cell adhered beta sub(2)-GPI was shown to induce functional effects potentially related to the pathogenesis of the clinical manifestations of APS such as thrombotic events and fetal loss. |
| doi_str_mv | 10.1006/jaut.2000.0412 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72545444</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0896841100904128</els_id><sourcerecordid>72545444</sourcerecordid><originalsourceid>FETCH-LOGICAL-c466t-3496b3fc9b1c811aaf52aad1f472aed92febd99de03925dacb47501be321df013</originalsourceid><addsrcrecordid>eNqFkUFv1DAQRi0EokvhyhH5xC2LJ7GTmNtqVaDSVqwEnC3HHrOuEru1vZX23zfp9sAF9TTSzJun0XyEfAS2BsbaL7f6WNY1Y2zNONSvyAqYFJUE0b0mK9bLtuo5wAV5l_MtYwBCiLfkYobaXkK3IvdXwcZywNHrkW5M8Q-6-BjocKJ6v_tKN3QfC4ayjPe6HOJfDFi8oTdoDjr4PFEXE50NdDv64M3M3cx9h7k8mTKN7mn86xRsihO-J2-cHjN-eK6X5M-3q9_bH9Xu5_fr7WZXGd62pWq4bIfGGTmA6QG0dqLW2oLjXa3RytrhYKW0yBpZC6vNwDvBYMCmBusYNJfk89l7l-L9cT5HTT4bHEcdMB6z6mrBBef8RRC6tgfWLOD6DJoUc07o1F3yk04nBUwtaaglDbWkoZY05oVPz-bjMKH9Bz-_fwb6M4DzIx48JpWNx2DQ-oSmKBv9_9yP3faadw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17681034</pqid></control><display><type>article</type><title>Endothelial Activation by aPL: A Potential Pathogenetic Mechanism for the Clinical Manifestations of the Syndrome</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Meroni, P.L ; Raschi, E ; Camera, M ; Testoni, C ; Nicoletti, F ; Tincani, A ; Khamashta, M.A ; Balestrieri, G ; Tremoli, E ; Hess, D.C</creator><creatorcontrib>Meroni, P.L ; Raschi, E ; Camera, M ; Testoni, C ; Nicoletti, F ; Tincani, A ; Khamashta, M.A ; Balestrieri, G ; Tremoli, E ; Hess, D.C</creatorcontrib><description>It is now generally accepted that antiphospholipid antibodies (aPL) rather than to be directed against PL themselves do recogize PL-binding proteins; beta sub(2)-Glycoprotein I ( beta sub(2)-GPI) has been shown to be the most important. beta sub(2)-Glycoprotein I is a highly cationic glycoprotein normally present in the serum and able to bind anionic structures including negatively charged PL. It displays several activities potentially related to the pathphysiology of the antiphospholipid symdrome (APS) by: (a) acting as a natural circulating anticoagulant, (b) potentiating platelet activation, and (c) interfering with the protein C/S system. More recently, beta sub(2)-GPI was found to adhere to human endothelial and trophoblast cell membranes and to offer suitable epitopes for circulating anti- beta sub(2)-GPI antibodies. The antibody binding to cell adhered beta sub(2)-GPI was shown to induce functional effects potentially related to the pathogenesis of the clinical manifestations of APS such as thrombotic events and fetal loss.</description><identifier>ISSN: 0896-8411</identifier><identifier>EISSN: 1095-9157</identifier><identifier>DOI: 10.1006/jaut.2000.0412</identifier><identifier>PMID: 10968917</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Animals ; Antibodies, Antiphospholipid - metabolism ; Antibodies, Antiphospholipid - physiology ; antiphospholipid syndrome ; Antiphospholipid Syndrome - immunology ; Antiphospholipid Syndrome - pathology ; Antiphospholipid Syndrome - physiopathology ; b2-glycoprotein I ; beta 2-Glycoprotein I ; endothelial cells, anti-β2-glycoprotein I antibodies, atherosclerosis, statins ; Endothelium, Vascular - immunology ; Endothelium, Vascular - pathology ; Endothelium, Vascular - physiopathology ; Glycoproteins - immunology ; Humans</subject><ispartof>Journal of Autoimmunity, 2000-09, Vol.15 (2), p.237-240</ispartof><rights>2000 Academic Press</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c466t-3496b3fc9b1c811aaf52aad1f472aed92febd99de03925dacb47501be321df013</citedby><cites>FETCH-LOGICAL-c466t-3496b3fc9b1c811aaf52aad1f472aed92febd99de03925dacb47501be321df013</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1006/jaut.2000.0412$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>313,314,780,784,792,3550,27922,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10968917$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Meroni, P.L</creatorcontrib><creatorcontrib>Raschi, E</creatorcontrib><creatorcontrib>Camera, M</creatorcontrib><creatorcontrib>Testoni, C</creatorcontrib><creatorcontrib>Nicoletti, F</creatorcontrib><creatorcontrib>Tincani, A</creatorcontrib><creatorcontrib>Khamashta, M.A</creatorcontrib><creatorcontrib>Balestrieri, G</creatorcontrib><creatorcontrib>Tremoli, E</creatorcontrib><creatorcontrib>Hess, D.C</creatorcontrib><title>Endothelial Activation by aPL: A Potential Pathogenetic Mechanism for the Clinical Manifestations of the Syndrome</title><title>Journal of Autoimmunity</title><addtitle>J Autoimmun</addtitle><description>It is now generally accepted that antiphospholipid antibodies (aPL) rather than to be directed against PL themselves do recogize PL-binding proteins; beta sub(2)-Glycoprotein I ( beta sub(2)-GPI) has been shown to be the most important. beta sub(2)-Glycoprotein I is a highly cationic glycoprotein normally present in the serum and able to bind anionic structures including negatively charged PL. It displays several activities potentially related to the pathphysiology of the antiphospholipid symdrome (APS) by: (a) acting as a natural circulating anticoagulant, (b) potentiating platelet activation, and (c) interfering with the protein C/S system. More recently, beta sub(2)-GPI was found to adhere to human endothelial and trophoblast cell membranes and to offer suitable epitopes for circulating anti- beta sub(2)-GPI antibodies. The antibody binding to cell adhered beta sub(2)-GPI was shown to induce functional effects potentially related to the pathogenesis of the clinical manifestations of APS such as thrombotic events and fetal loss.</description><subject>Animals</subject><subject>Antibodies, Antiphospholipid - metabolism</subject><subject>Antibodies, Antiphospholipid - physiology</subject><subject>antiphospholipid syndrome</subject><subject>Antiphospholipid Syndrome - immunology</subject><subject>Antiphospholipid Syndrome - pathology</subject><subject>Antiphospholipid Syndrome - physiopathology</subject><subject>b2-glycoprotein I</subject><subject>beta 2-Glycoprotein I</subject><subject>endothelial cells, anti-β2-glycoprotein I antibodies, atherosclerosis, statins</subject><subject>Endothelium, Vascular - immunology</subject><subject>Endothelium, Vascular - pathology</subject><subject>Endothelium, Vascular - physiopathology</subject><subject>Glycoproteins - immunology</subject><subject>Humans</subject><issn>0896-8411</issn><issn>1095-9157</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUFv1DAQRi0EokvhyhH5xC2LJ7GTmNtqVaDSVqwEnC3HHrOuEru1vZX23zfp9sAF9TTSzJun0XyEfAS2BsbaL7f6WNY1Y2zNONSvyAqYFJUE0b0mK9bLtuo5wAV5l_MtYwBCiLfkYobaXkK3IvdXwcZywNHrkW5M8Q-6-BjocKJ6v_tKN3QfC4ayjPe6HOJfDFi8oTdoDjr4PFEXE50NdDv64M3M3cx9h7k8mTKN7mn86xRsihO-J2-cHjN-eK6X5M-3q9_bH9Xu5_fr7WZXGd62pWq4bIfGGTmA6QG0dqLW2oLjXa3RytrhYKW0yBpZC6vNwDvBYMCmBusYNJfk89l7l-L9cT5HTT4bHEcdMB6z6mrBBef8RRC6tgfWLOD6DJoUc07o1F3yk04nBUwtaaglDbWkoZY05oVPz-bjMKH9Bz-_fwb6M4DzIx48JpWNx2DQ-oSmKBv9_9yP3faadw</recordid><startdate>20000901</startdate><enddate>20000901</enddate><creator>Meroni, P.L</creator><creator>Raschi, E</creator><creator>Camera, M</creator><creator>Testoni, C</creator><creator>Nicoletti, F</creator><creator>Tincani, A</creator><creator>Khamashta, M.A</creator><creator>Balestrieri, G</creator><creator>Tremoli, E</creator><creator>Hess, D.C</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20000901</creationdate><title>Endothelial Activation by aPL: A Potential Pathogenetic Mechanism for the Clinical Manifestations of the Syndrome</title><author>Meroni, P.L ; Raschi, E ; Camera, M ; Testoni, C ; Nicoletti, F ; Tincani, A ; Khamashta, M.A ; Balestrieri, G ; Tremoli, E ; Hess, D.C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c466t-3496b3fc9b1c811aaf52aad1f472aed92febd99de03925dacb47501be321df013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Animals</topic><topic>Antibodies, Antiphospholipid - metabolism</topic><topic>Antibodies, Antiphospholipid - physiology</topic><topic>antiphospholipid syndrome</topic><topic>Antiphospholipid Syndrome - immunology</topic><topic>Antiphospholipid Syndrome - pathology</topic><topic>Antiphospholipid Syndrome - physiopathology</topic><topic>b2-glycoprotein I</topic><topic>beta 2-Glycoprotein I</topic><topic>endothelial cells, anti-β2-glycoprotein I antibodies, atherosclerosis, statins</topic><topic>Endothelium, Vascular - immunology</topic><topic>Endothelium, Vascular - pathology</topic><topic>Endothelium, Vascular - physiopathology</topic><topic>Glycoproteins - immunology</topic><topic>Humans</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Meroni, P.L</creatorcontrib><creatorcontrib>Raschi, E</creatorcontrib><creatorcontrib>Camera, M</creatorcontrib><creatorcontrib>Testoni, C</creatorcontrib><creatorcontrib>Nicoletti, F</creatorcontrib><creatorcontrib>Tincani, A</creatorcontrib><creatorcontrib>Khamashta, M.A</creatorcontrib><creatorcontrib>Balestrieri, G</creatorcontrib><creatorcontrib>Tremoli, E</creatorcontrib><creatorcontrib>Hess, D.C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of Autoimmunity</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Meroni, P.L</au><au>Raschi, E</au><au>Camera, M</au><au>Testoni, C</au><au>Nicoletti, F</au><au>Tincani, A</au><au>Khamashta, M.A</au><au>Balestrieri, G</au><au>Tremoli, E</au><au>Hess, D.C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Endothelial Activation by aPL: A Potential Pathogenetic Mechanism for the Clinical Manifestations of the Syndrome</atitle><jtitle>Journal of Autoimmunity</jtitle><addtitle>J Autoimmun</addtitle><date>2000-09-01</date><risdate>2000</risdate><volume>15</volume><issue>2</issue><spage>237</spage><epage>240</epage><pages>237-240</pages><issn>0896-8411</issn><eissn>1095-9157</eissn><abstract>It is now generally accepted that antiphospholipid antibodies (aPL) rather than to be directed against PL themselves do recogize PL-binding proteins; beta sub(2)-Glycoprotein I ( beta sub(2)-GPI) has been shown to be the most important. beta sub(2)-Glycoprotein I is a highly cationic glycoprotein normally present in the serum and able to bind anionic structures including negatively charged PL. It displays several activities potentially related to the pathphysiology of the antiphospholipid symdrome (APS) by: (a) acting as a natural circulating anticoagulant, (b) potentiating platelet activation, and (c) interfering with the protein C/S system. More recently, beta sub(2)-GPI was found to adhere to human endothelial and trophoblast cell membranes and to offer suitable epitopes for circulating anti- beta sub(2)-GPI antibodies. The antibody binding to cell adhered beta sub(2)-GPI was shown to induce functional effects potentially related to the pathogenesis of the clinical manifestations of APS such as thrombotic events and fetal loss.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>10968917</pmid><doi>10.1006/jaut.2000.0412</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0896-8411 |
| ispartof | Journal of Autoimmunity, 2000-09, Vol.15 (2), p.237-240 |
| issn | 0896-8411 1095-9157 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72545444 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Animals Antibodies, Antiphospholipid - metabolism Antibodies, Antiphospholipid - physiology antiphospholipid syndrome Antiphospholipid Syndrome - immunology Antiphospholipid Syndrome - pathology Antiphospholipid Syndrome - physiopathology b2-glycoprotein I beta 2-Glycoprotein I endothelial cells, anti-β2-glycoprotein I antibodies, atherosclerosis, statins Endothelium, Vascular - immunology Endothelium, Vascular - pathology Endothelium, Vascular - physiopathology Glycoproteins - immunology Humans |
| title | Endothelial Activation by aPL: A Potential Pathogenetic Mechanism for the Clinical Manifestations of the Syndrome |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T00%3A58%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Endothelial%20Activation%20by%20aPL:%20A%20Potential%20Pathogenetic%20Mechanism%20for%20the%20Clinical%20Manifestations%20of%20the%20Syndrome&rft.jtitle=Journal%20of%20Autoimmunity&rft.au=Meroni,%20P.L&rft.date=2000-09-01&rft.volume=15&rft.issue=2&rft.spage=237&rft.epage=240&rft.pages=237-240&rft.issn=0896-8411&rft.eissn=1095-9157&rft_id=info:doi/10.1006/jaut.2000.0412&rft_dat=%3Cproquest_cross%3E72545444%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17681034&rft_id=info:pmid/10968917&rft_els_id=S0896841100904128&rfr_iscdi=true |